An observational study in Aortic Valve Stenosis, sponsored by Sahajanand Medical Technologies Limited. Withdrawn at 4 sites in Italy. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-08-18.
Sponsored by Sahajanand Medical Technologies Limited · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 118 studies in Aortic Valve Stenosis with a site in Italy — 39 open to participants now, 54 under way, 1 of them phase 3. Aortic Valve Stenosis · Italy.
Among the 118 studies in Aortic Valve Stenosis with a site in Italy, this one is the 71st largest by enrollment of the 71 observational ones that give a count, is one of 10 that started in 2023, is one of 71 observational ones, and was the 92nd registered.
1,028 studies on the registry are indexed under Aortic Valve Stenosis; 295 are open to participants now.
Browse Aortic Valve Stenosis studies →39 of the 118 studies in Aortic Valve Stenosis with a site in Italy are open now. Recruiting first, the newest first:
University Hospital of Ferrara · Sites in Italy
Ages 75+
University Hospital of Ferrara · Sites in Italy
Azienda Ospedaliera "Sant'Andrea" · Sites in Italy
Ages 18+
IRCCS Policlinico S. Donato · Sites in Italy
Ages 18+
IRCCS Policlinico S. Donato · Sites in Italy
Ages 18+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 24 take children under 18; 14 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
118 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 10 started in 2023.
By drug class, each counting the studies that test any of its medicines:
Median enrollment 300 across the 47 interventional studies, 500 across the 71 observational. Of the 53 that completed or were terminated, 15 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
52 of 118 have an industry lead sponsor. The 10 most frequent:
Sahajanand Medical Technologies Limited is the lead sponsor of 12 studies on the registry; 4 are open to participants now.
Sahajanand Medical Technologies Limited has 3 studies filed under Aortic Valve Stenosis — fewer than ten, so there is no comparison to draw.
9 of the studies in Aortic Valve Stenosis with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07620925Azienda Ospedaliera "Sant'Andrea"Derivation and Validation of the Aortic Valve Echocardiographic Calcium Score to Confirm Severe Aortic Stenosis: the Echo-AVCS Study | 2026-12-31 |
| NCT06859255IRCCS Policlinico S. DonatoIn-vitro Benchmarking of Currently Available Heart Valve Prostheses for Surgical and Percutaneous Treatment of Aortic Stenosis With Small Annulus, Followed by In-vivo Validation | 2027-02-07 |
| NCT05779787Niguarda HospitalCOronary Re-engageMent aFter randOm NavitoR alignmenT (COMFORT STUDY) | 2027-02-15 |
| NCT05751577Azienda Usl di BolognaTRanscatheter Aortic-Valve Implantation With or Without On-site Cardiac Surgery: the TRACS Trial | 2027-03-31 |
| NCT05932615Abbott Medical DevicesENVISION IDE Trial: Safety and Effectiveness of NAVITOR in Transcatheter Aortic Valve Implantation | 2027-04 |
Add all 9 to your calendar (.ics) → With an account.
Among the 118 studies in Aortic Valve Stenosis with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Hydra-IT is a multicenter observational study aim to collect clinical, procedural and follow-up data and evaluate the short, medium and long term results of Hydra TAVI System in patient with severe aortic stenosis.
Hydra-IT is a multicenter observational study conducted across different centres in Italy. The primary objective of the study is to evaluate the safety and efficacy of transcatheter aortic valve implantation and clinical outcome in patients treated with Hydra device. Secondary objective is to evaluate the long term (up to 5 years) effectiveness and the quality of treatment using Hydra device. Patients with severe stenosis symptomatic of the native aortic valve or bioprosthesis in a degenerated aortic position will be included in this study.
Patient with severe aortic valve stenosis
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The Hydra device is self-expanding transcatheter aortic valve consists of a self-expanding nitinol frame and three bovine pericardial leaflets in supra-annular position.
Cardiovascular mortality
Time frame: 30 days
All-cause mortality
Cardiovascular mortality, valve-related mortality, and non-cardiovascular mortality
Time frame: 30 days, 6 months, 1 year, 2 years, 3 years, 4 years, 5 years
All stroke
Disabling and non-disabling stroke
Time frame: 30 days, 6 months, 1 year, 2 years, 3 years, 4 years, 5 years
Disabling stroke
Time frame: 30 days, 6 months, 1 year, 2 years, 3 years, 4 years, 5 years
Myocardial infarction
Time frame: 30 days, 6 months, 1 year, 2 years, 3 years, 4 years, 5 years
Life-threatening or disabling bleeding
Time frame: 30 days
Major vascular complications
Time frame: 30 days
Acute kidney injury (Stage 2 or 3)
Time frame: 30 days
New permanent pacemaker implantation (PPM)
Time frame: 30 days, 6 months, 1 year, 2 years, 3 years, 4 years, 5 years
Paravalvular Leak (PVL)
Time frame: 30 days, 6 months, 1 year, 2 years, 3 years, 4 years, 5 years
Effective Orifice Area (EOA)
Time frame: 30 days, 6 months, 1 year, 2 years, 3 years, 4 years, 5 years
Mean aortic valve gradient
Time frame: 30 days, 6 months, 1 year, 2 years, 3 years, 4 years, 5 years
New York Heart Association (NYHA) functional classification
Time frame: 30 days, 6 months, 1 year, 2 years, 3 years, 4 years, 5 years
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2023 (actual). Primary completion is estimated for Jul 2027, 48 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is withdrawn, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sahajanand Medical Technologies Limited